Checkpoint Therapeutics Inc (CKPT):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C9852)
◆英語タイトル:Checkpoint Therapeutics Inc (CKPT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9852
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:39
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Checkpoint Therapeutics Inc (Checkpoint Therapeutics), a subsidiary of Fortress Biotech Inc, is a clinical-stage biopharmaceutical company that acquires, develops and commercializes non-chemotherapy and immune enhanced combination treatments for the treatment of solid tumor cancers. The company’s lead product candidate, CK-301 human antagonistic antibody intended for the treatment of patients with non-small cell lung cancer (NSCLC) and other solid tumors. Its other pipeline products includes a portfolio of human immuno-oncology agents and targeted anti-cancer agents intended for the treatment of multiple types of cancer including renal cell carcinoma, EGFR mutation-positive NSCLC and multiple forms of cancer. The company also works in partnership with other pharmaceutical companies to co-develop its antibodies. Checkpoint Therapeutics is headquartered in New York, the US.

Checkpoint Therapeutics Inc (CKPT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Checkpoint Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Checkpoint Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Checkpoint Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Checkpoint Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Checkpoint Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Checkpoint Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Checkpoint Therapeutics Raises USD57.8 Million Venture Financing 11
Partnerships 12
Applied BioMath Enters into Agreement with Checkpoint Therapeutics 12
Checkpoint Therapeutics Enters into Research Agreement with NeuPharma 13
TG Therapeutics Extends its Option Agreement with Checkpoint Therapeutics 14
TG Therapeutics Enters into Agreement with Checkpoint Therapeutics to Develop and Commercialize Immuno-Oncology Targeted Antibodies 15
Licensing Agreements 16
Checkpoint Therapeutics Amends its Licensing Agreement with Jubilant Biosys 16
Checkpoint Therapeutics Enters into Licensing Agreement with Cephalon 17
Checkpoint Therapeutics Amends its Licensing Agreement with Dana-Farber Cancer Institute 18
Equity Offering 20
Checkpoint Therapeutics Prices Public Offering of Shares for USD20 Million 20
Checkpoint Therapeutics Plans to Raise up to USD100 Million in Public Offering of Shares 22
Checkpoint Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 23
Checkpoint Therapeutics Raises USD0.6 Million in Private Placement of Units 24
Checkpoint Therapeutics Raises USD58 Million in Private Placement of Units 25
Checkpoint Therapeutics Inc – Key Competitors 26
Checkpoint Therapeutics Inc – Key Employees 27
Checkpoint Therapeutics Inc – Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Financial Announcements 29
Nov 02, 2018: Checkpoint Therapeutics reports third quarter 2018 financial results and recent corporate highlights 29
Aug 07, 2018: Checkpoint Therapeutics announces second quarter 2018 financial results 30
May 10, 2018: Checkpoint Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights 31
Mar 15, 2018: Checkpoint Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results 32
Corporate Communications 33
Oct 16, 2018: Checkpoint Therapeutics names Christian Bechon to its Board of Directors 33
Clinical Trials 34
Apr 18, 2018: Checkpoint Therapeutics Reports Preclinical Data on BET Inhibitor CK-103 at the American Association for Cancer Research Annual Meeting 34
Mar 15, 2018: TG Therapeutics Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research Annual Meeting 35
Mar 15, 2018: TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting 36
Mar 20, 2017: Checkpoint Therapeutics to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2017 37
Other Significant Developments 38
Jan 11, 2018: Adimab Initiates Update on Clinical Progression of Partner Programs 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39

List of Tables
Checkpoint Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Checkpoint Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Checkpoint Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Checkpoint Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Checkpoint Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Checkpoint Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Checkpoint Therapeutics Raises USD57.8 Million Venture Financing 11
Applied BioMath Enters into Agreement with Checkpoint Therapeutics 12
Checkpoint Therapeutics Enters into Research Agreement with NeuPharma 13
TG Therapeutics Extends its Option Agreement with Checkpoint Therapeutics 14
TG Therapeutics Enters into Agreement with Checkpoint Therapeutics to Develop and Commercialize Immuno-Oncology Targeted Antibodies 15
Checkpoint Therapeutics Amends its Licensing Agreement with Jubilant Biosys 16
Checkpoint Therapeutics Enters into Licensing Agreement with Cephalon 17
Checkpoint Therapeutics Amends its Licensing Agreement with Dana-Farber Cancer Institute 18
Checkpoint Therapeutics Prices Public Offering of Shares for USD20 Million 20
Checkpoint Therapeutics Plans to Raise up to USD100 Million in Public Offering of Shares 22
Checkpoint Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 23
Checkpoint Therapeutics Raises USD0.6 Million in Private Placement of Units 24
Checkpoint Therapeutics Raises USD58 Million in Private Placement of Units 25
Checkpoint Therapeutics Inc, Key Competitors 26
Checkpoint Therapeutics Inc, Key Employees 27

List of Figures
Checkpoint Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Checkpoint Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Checkpoint Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Checkpoint Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Checkpoint Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Checkpoint Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Checkpoint Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Checkpoint Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Checkpoint Therapeutics Inc (CKPT):製薬・医療:M&Aディール及び事業提携情報(Checkpoint Therapeutics Inc (CKPT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆